The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance.

Resistance to antibiotics is becoming a major problem worldwide. Exacerbating this situation is the fact that few new antibiotics are in the development pipeline, and, indeed, no novel class of antibiotics has been introduced into medical practice in more than 20 years. It is proposed that the solutions to the problem of antibiotic resistance will be found only through fundamental research that will probably use biotechnology as a tool. A variety of novel approaches being utilized in university laboratories and biotechnology companies are outlined. Two approaches in particular, namely, Synsorbs and recombinant cationic peptide antimicrobials, that have been developed through the Canadian Bacterial Diseases Network, a national research consortium, are discussed.

[1]  R. Hancock,et al.  Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification , 1994, Antimicrobial Agents and Chemotherapy.

[2]  R. Houghten,et al.  Rapid identification of compounds with enhanced antimicrobial activity by using conformationally defined combinatorial libraries. , 1996, The Biochemical journal.

[3]  G. Armstrong,et al.  A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. , 1995, The Journal of infectious diseases.

[4]  J. K. Seydel Modern Strategies in the Design of Antimicrobial Agents , 1989 .

[5]  J. Travis,et al.  Reviving the antibiotic miracle? , 1994, Science.

[6]  P. Pizzo,et al.  Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  H. Neu Infection problems for the 1990's--do we have an answer? , 1993, Scandinavian journal of infectious diseases. Supplementum.

[8]  R. Hancock,et al.  Recombinant DNA procedures for producing small antimicrobial cationic peptides in bacteria. , 1993, Gene.

[9]  G. Dougan,et al.  Molecular characterization of bacterial virulence factors and the consequences for vaccine design. The 1988 Fleming lecture. , 1989, Journal of general microbiology.

[10]  R. Hancock,et al.  Antimicrobial peptides: broad-spectrum antibiotics from nature. , 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  N. Farnsworth,et al.  Ethnopharmacology and drug development. , 1994, Ciba Foundation symposium.

[12]  R E Hancock,et al.  Canadian Bacterial Diseases Network: a new approach to university-industry relationships. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[13]  D. Livermore Determinants of the activity of beta-lactamase inhibitor combinations. , 1993, The Journal of antimicrobial chemotherapy.